Graham Capital Management L.P. Purchases Shares of 18,954 AnaptysBio, Inc. (NASDAQ:ANAB)

Graham Capital Management L.P. purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 18,954 shares of the biotechnology company's stock, valued at approximately $251,000. Graham Capital Management L.P. owned about 0.06% of AnaptysBio as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its holdings in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of AnaptysBio in the 4th quarter worth about $40,000. AlphaQuest LLC boosted its stake in shares of AnaptysBio by 1,891.5% during the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 4,237 shares during the period. Virtus ETF Advisers LLC boosted its stake in shares of AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of AnaptysBio by 1,585.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 5,360 shares during the period.

AnaptysBio Trading Down 0.9%

AnaptysBio stock opened at $20.22 on Monday. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31. The stock has a market cap of $594.06 million, a P/E ratio of -3.33 and a beta of -0.20. The company has a 50-day moving average price of $18.97 and a 200 day moving average price of $18.24.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $27.77 million during the quarter, compared to analysts' expectations of $15.27 million. As a group, analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has initiated a share repurchase program on Monday, March 24th that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the biotechnology company to reacquire up to 13.1% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Analyst Ratings Changes

Several brokerages have recently weighed in on ANAB. Wedbush reaffirmed an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 1st. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. HC Wainwright reiterated a "neutral" rating and set a $22.00 price objective on shares of AnaptysBio in a research note on Tuesday, March 4th. Wells Fargo & Company boosted their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Finally, Guggenheim upped their price target on shares of AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $35.88.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.